Moreover, the observation that miR-183 and miR-22 expression was elevated in the low, compared to the high form of metastatic cancer, coupled with the fact that increasing the expression of miR-183 and miR-22 resulted in EZRIN reduction, led to the conclusion that EZRIN inactivation through miR-183 and miR-22 can inhibit ovarian cancer metastasis [92]. Here, EZR is linked to ovarian carcinoma.